First Manhattan’s IGM Biosciences IGMS Stock Holding History

First Manhattan’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-172,200	Closed	-$1.44M	–	1500
2023 Q3	$1.44M	Buy	+172,200	New	+$1.46M	0.01%	349

Other funds holding IGMS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

First Manhattan's IGMS Position: Q4 2023 in Review

First Manhattan sold out of IGM Biosciences (IGMS) in Q4 2023, closing a stake of 172,200 shares — an estimated $1.44M sold.

First Manhattan first reported a position in IGMS in Q3 2023 and held it in 1 quarter. The position peaked at $1.44M in Q3 2023. 72 funds tracked by Wall St. Rank hold IGMS as of Q4 2023.

First Manhattan reported no remaining IGM Biosciences position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 172,200 IGM Biosciences shares in Q4 2023, an estimated $1.44M.
First Manhattan first reported a position in IGM Biosciences in Q3 2023 and held it in 1 quarter.
First Manhattan's IGM Biosciences position peaked at $1.44M in Q3 2023.
72 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.